SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

POET Technologies, Inc. engages in the designing, developing, manufacturing and sale of opto-electronic solutions for the sensing, data communications and telecommunications markets. It developed POET Optical Interposer platform, which allows the integration of electronic and photonic devices into a single multi-chip module. The company was founded on November 14, 1985 and is headquartered in Toronto, Canada.

POET Technologies Inc

POET Technologies is trending sharply lower after announcing that Marvell canceled all purchase orders inherited from its acquisition of Celestial AI due to an alleged breach of confidentiality. Investors and community members are expressing significant frustration over management's handling of the disclosure, leading to widespread speculation about the company's future contracts and immediate valuation.

Intellia Therapeutics, Inc. is a clinical stage genome editing company, which engages in the development of curative therapeutics using the CRISPR/Cas9 system. Its CRISPR/Cas9 system transforms medicine by both producing therapeutics that permanently edit and/or correct disease-associated genes in the human body with a single treatment course, and creates engineered cells that can treat oncological and immunological diseases. The company was founded by Andrew May, Luciano Marraffini, Rodolphe Barrangou, Nessan Bermingham, Rachel Haurwitz, Erik Sontheimer, Jennifer Doudna, and Derrick Rossi in May 2014 and is headquartered in Cambridge, MA.

Intellia Therapeutics Inc

Intellia Therapeutics is currently a focal point for investors as they await topline Phase 3 data from the HAELO trial, which the community sees as a potential validation for their in vivo CRISPR platform. Traders are actively debating the high short interest and the stock's susceptibility to a squeeze, with many weighing the clinical promise of a functional HAE cure against the broader volatility affecting the biotech sector.

QUALCOMM, Inc. engages in developing and commercializing foundational technologies and products used in mobile devices and other wireless products. It operates through the following segments: Qualcomm CDMA Technologies (QCT), Qualcomm Technology Licensing (QTL), and Qualcomm Strategic Initiatives (QSI). The QCT segment develops and supplies integrated circuits and system software based on technologies for use in voice and data communications, networking, application processing, multimedia, and global positioning system products. The QTL segment grants licenses and provides rights to use portions of the firm's intellectual property portfolio. The QSI segment focuses on opening new or expanding opportunities for its technologies and supporting the design and introduction of new products and services for voice and data communications. The company was founded by Franklin P. Antonio, Adelia A. Coffman, Andrew Cohen, Klein Gilhousen, Irwin Mark Jacobs, Andrew J. Viterbi, and Harvey P. White in July 1985 and is headquartered in San Diego, CA.

Qualcomm, Inc.

Qualcomm is trending as investors weigh strong AI and automotive growth potential against near-term headwinds like supply chain constraints and cautious analyst sentiment. The stock is a primary focus for the community, which remains divided on whether the current price represents a buying opportunity or a deeper structural decline.

Rumble, Inc. engages in operating an online neutral video platform. It operates through the following geographical segments: United States, Canada, and Other. The company was founded in October 2013 by Chris Pavlovski and is headquartered in Longboat Key, FL.

Rumble Inc - Ordinary Shares - Class A

Rumble Inc

Rumble is experiencing significant bullish momentum driven by heavy short interest and mounting anticipation for its acquisition of Northern Data, which effectively expands its cloud and GPU infrastructure. The community is actively discussing a potential short squeeze, citing record-high short interest and strong backing from strategic partner Tether as catalysts for a potential rally.

Arm Holdings Plc engages in the licensing, marketing, research, and development of microprocessors, systems IP, graphics processing units, physical IP and associated systems IP, software, and tools. It operates through the following geographical segments: United Kingdom, United States, and Other Countries. The company was founded on November 12, 1990 and is headquartered in Cambridge, the United Kingdom.

Arm Holdings plc. - ADR

Arm Holdings Plc.

Arm Holdings is experiencing significant market movement driven by speculative interest in its shift toward custom AI chip design and high-performance server CPUs. Community discussions are split between euphoria over its long-term potential as an AI infrastructure backbone and intense debate regarding its valuation, with many traders actively debating the merits of aggressive shorting versus holding for a potential parabolic breakout.

Alpha Tau Medical Ltd. is a clinical-stage oncology therapeutics company, which focuses on the research, development, and commercialization of diffusing alpha-emitters radiation therapy for the treatment of cancer. The firm is involved in the clinical trials at cancer centers with indications that include skin cancer, oral cavity cancer, breast cancer, and pancreatic cancer. The company was founded by Uzi Sofer, Yona Keisari, and Itzhak Kelson in November 2015 and is headquartered in Jerusalem, Israel.

Alpha Tau Medical Ltd

ALPHA TAU MEDICAL LTD

Alpha Tau Medical is drawing significant investor interest as it approaches a high-profile oral presentation of pancreatic cancer data at Digestive Disease Week, which the community views as a critical catalyst for the stock. Traders are actively accumulating shares, citing strong scientific momentum and the company's progress in expanding global clinical trials.

Direxion Shares ETF Trust - Direxion Daily Semiconductor Bull 3X ETF

Direxion Daily Semiconductor Bull 3X Shares

Direxion Daily Semiconductor Bull 3X Shares is experiencing massive volatility and bullish momentum driven by a strong semiconductor sector rally, fueled by earnings optimism and ongoing AI infrastructure spending. Investors are actively debating whether the current parabolic price action signifies a sustainable super-cycle or a speculative bubble, leading to intense sentiment clashes between bullish 'diamond hands' and traders betting on a sharp mean reversion.

Sagimet Biosciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of novel therapeutics for the treatment of infectious diseases. Its lead drug candidate, denifanstat, is an oral, once-daily pill and selective fatty acid synthase (FASN) inhibitor in development for the treatment of nonalcoholic steatohepatitis (NASH). The company was founded by Urs F. Greber, Ari Helenius, and Lucas Pelkmans on December 19, 2006 and is headquartered in San Mateo, CA.

Sagimet Biosciences Inc - Ordinary Shares - Series A

Sagimet Biosciences Inc

Sagimet Biosciences is currently seeing significant investor attention driven by positive Phase 3 acne data and the potential for its FASN inhibitor denifanstat as a cornerstone MASH treatment. The community is actively debating the company's valuation, the strategic shift toward combination therapies, and the high probability of a future buyout given the surge in M&A activity within the metabolic disease sector.

Direxion Shares ETF Trust - Direxion Daily Semiconductor Bear 3X ETF

Direxion Daily Semiconductor Bear 3X Shares

The Direxion Daily Semiconductor Bear 3X Shares (SOXS) is seeing intense volatility and record-breaking volume as traders debate whether the semiconductor sector's prolonged winning streak represents an unsustainable AI bubble or a resilient super-cycle. Community sentiment remains deeply polarized between aggressive short-sellers betting on a mean reversion and bulls who argue that relentless momentum and capital rotation into chip-related infrastructure make shorting the sector a high-risk trade.

X-Energy, Inc. operates as an energy company The firm focuses on modular nuclear reactors and fuel technology for clean energy generation. The company was founded by Kam Ghaffarian and Eben Mulder on 2009 and is headquartered in Rockville, MD.

X-Energy Inc. - Ordinary Shares- Class A

X-energy Inc

X-energy is generating significant investor buzz as it makes its market debut, with the community highlighting its strategic backing from major players like Amazon and Dow to address the surging energy demands of AI data centers. Traders are actively debating the company's valuation and long-term potential compared to other modular nuclear reactor peers, fueled by high initial demand and its positioning as a key player in the clean energy infrastructure space.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>Sagimet plans to launch a Phase 3 U.S. trial of Denifanstat in the second half of 2026 following positive late-stage results in China, which showed a favorable safety profile.</li><li>The biotech firm priced a public offering of about 29.2 million shares of its Series A common stock at $6 per share, a 2.4% premium over its closing price on Friday.</li><li>Sagimet said the combined cash from the offering and its existing reserves should fund its acne programs through 2028.</li></ul>Shares of Sagimet Biosciences (SGMT) jumped more than 40% on Monday, breaking the 200-day moving average for the first time since early February, after the company priced its latest share offering at a premium and reported positive progress on its acne drug.<a href="https://stocktwits.com/symbol/SGMT">SGMT shares</a> recorded their biggest intraday gains in more than 27 months, rising to their highest levels in over 5 months.<img src="https://news.stocktwits-cdn.com/SGMT_jpg_9df53f672c.webp" alt="SGMT.jpg">Source: TradingView<h2 class="st-heading-2">$175M Offering To Boost Acne Treatment Pipeline</h2>Sagimet priced a public offering of about 29.2 million shares of its Series A common stock at $6 per share, aiming to raise roughly $175 million in gross proceeds. This represented a 2.4% premium to the stock’s closing price on Friday. The offering is expected to close around April 28, 2026.The clinical-stage biotech firm plans to use the funds to advance its pipeline, including a Phase 3 trial of its lead drug candidate Denifanstat for acne. Proceeds will also support the development of TVB-3567, a small-molecule inhibitor of fatty acid synthase (FASN) for acne treatment.Sagimet said the combined cash from the offering and its existing reserves should fund its acne programs through 2028, including key trial readouts. The remaining funds will be used for general corporate purposes, including clinical development, working capital, and operating expenses.<h2 class="st-heading-2">Denisfanstat Acne Treatment In Focus</h2>Sagimet is advancing its acne treatment pipeline, with plans to launch a Phase 3 U.S. trial of Denifanstat in the second half of 2026. The move follows positive late-stage results in China, where the once-daily oral therapy showed good safety and sustained improvement in patients with moderate to severe acne.The company is also progressing its broader pipeline. Sagiment announced plans to move its TVB-3567, currently in a Phase 1 trial, into Phase 2 studies later this year. Meanwhile, development in metabolic dysfunction-associated steatohepatitis (MASH) is expected to be paused until the company secures non-dilutive funding.<h2 class="st-heading-2">How Did Retail Traders React?</h2>Retail sentiment on Stocktwits turned ‘extremely bullish’ from ‘bullish’ a day earlier, while message volumes on the platform remained ‘extremely high.’One user said the company’s acne treatment “has blockbuster potential.”<stembedurl>https://stocktwits.com/Expharmaguy/message/651485936</stembedurl>Another user said SGMT is “now a $50-100 value stock” given the “resoundingly positive phase 3” trial.<stembedurl>https://stocktwits.com/Market_Max/message/651490482</stembedurl>The stock has gained around 40% so far this year.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/tesla-stock-elon-musk-pay-package-share-registration-what-it-means/cZBNYDmReP3">TSLA Stock In Spotlight As EV Maker Registers Shares Tied To Elon Musk’s 2018 Pay Package – Retail Sees Imminent Sell-Off</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on technology background. INTC and AMD hit fresh records on Thursday. (Image source: Getty Images)

SGMT Stock Surged 40% And Breached 200-DMA For The First Time In Nearly 3 Months – What’s Got Retail Buzzing?

The firm announced positive late-stage results in China for its lead drug candidate to treat acne, and priced its $175M offering at a premium. 

Equity

Sagimet Biosciences Inc. (NASDAQ:SGMT) Receives Consensus Rating of "Moderate Buy" from Analysts

Shares of Sagimet Biosciences Inc. (NASDAQ:SGMT - Get Free Report) have been given a consensus recommendation of "Moderate Buy" by the eleven ratings firms that are presently covering the company, Marketbeat reports. One research analyst has rated the stock with a sell rating, two have assigned a...

Sagimet Names Andreas Grauer CMO

(RTTNews) - Sagimet Biosciences Inc. (SGMT), on Monday announced the appointment of Andreas Grauer as Chief Medical Officer, effective April 20...

Sagimet Biosciences Inc. (NASDAQ:SGMT) Short Interest Down 15.2% in March

Sagimet Biosciences Inc. (NASDAQ:SGMT - Get Free Report) saw a significant decrease in short interest in March. As of March 31st, there was short interest totaling 3,225,311 shares, a decrease of...

Shares of Sagimet Biosciences Inc. (NASDAQ:SGMT - Get Free Report) have been given a consensus recommendation of "Moderate Buy" by the eleven brokerages that are currently covering the firm...

Sagimet Biosciences (NASDAQ:SGMT) Now Covered by Rodman & Renshaw

Rodman & Renshaw assumed coverage on shares of Sagimet Biosciences in a research report on Thursday. They set a "buy" rating and a $28.00 price objective for the company...

Sagimet Biosciences (SGMT) Expected to Announce Quarterly Earnings on Monday

Sagimet Biosciences (NASDAQ:SGMT) will be releasing its Q4 2025 earnings on Monday, March 30. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2026-3-30-sagimet-biosciences-inc-series-a-stock...

HC Wainwright Has Negative Outlook for SGMT FY2027 Earnings

Sagimet Biosciences Inc. (NASDAQ:SGMT - Free Report) - Analysts at HC Wainwright dropped their FY2027 earnings per share (EPS) estimates for Sagimet Biosciences in a report issued on Wednesday, March...

Sagimet Biosciences (NASDAQ:SGMT) Upgraded to "Hold" at Wall Street Zen

Wall Street Zen raised Sagimet Biosciences from a "sell" rating to a "hold" rating in a research note on Saturday...

Q1 Earnings Forecast for SGMT Issued By HC Wainwright

Sagimet Biosciences Inc. (NASDAQ:SGMT - Free Report) - Equities researchers at HC Wainwright issued their Q1 2026 earnings per share estimates for Sagimet Biosciences in a research report issued on...

Up 5%

Down 5%

Show me the results

Which direction is the next 5% move for the S&amp;P 500?

Stocktwits

Which direction is the next 5% move for the S&P 500?

Stocktwits Polls

Traders are debating whether a $175M stock offering acts as a growth-funding catalyst or harmful dilution for the biotech.

Strategic news regarding the initiation of Phase 3 clinical trials for denifanstat has sparked significant bullish optimism.

Technical traders are closely monitoring price action above key resistance levels to determine the next major trend movement.

Debates persist between those expecting a massive short squeeze and others viewing the recent price action as a classic pump.

SGMT
Sagimet Biosciences Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest SGMT News

SGMTSagimet Biosciences Inc